These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 9372064)
41. Hydroxyurea therapy in children severely affected with sickle cell disease. Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542 [TBL] [Abstract][Full Text] [Related]
42. Measurements of red cell deformability and hydration reflect HbF and HbA Parrow NL; Tu H; Nichols J; Violet PC; Pittman CA; Fitzhugh C; Fleming RE; Mohandas N; Tisdale JF; Levine M Blood Cells Mol Dis; 2017 Jun; 65():41-50. PubMed ID: 28472705 [TBL] [Abstract][Full Text] [Related]
43. Sickle Cell Disease: A Primer for Primary Care Providers. Kimrey S; Saving KL Pediatr Ann; 2020 Jan; 49(1):e43-e49. PubMed ID: 31930422 [TBL] [Abstract][Full Text] [Related]
44. The role of hydroxyurea in sickle cell disease. Halsey C; Roberts IA Br J Haematol; 2003 Jan; 120(2):177-86. PubMed ID: 12542474 [No Abstract] [Full Text] [Related]
45. Long-term use of hydroxyurea for sickle cell anemia. Hagar W JAMA; 2003 Aug; 290(6):753; author reply 754. PubMed ID: 12915424 [No Abstract] [Full Text] [Related]
46. Haemoglobin F modulation in childhood sickle cell disease. Trompeter S; Roberts I Br J Haematol; 2009 Feb; 144(3):308-16. PubMed ID: 19036119 [TBL] [Abstract][Full Text] [Related]
47. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature]. Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961 [TBL] [Abstract][Full Text] [Related]
48. Genomic polymorphisms in sickle cell disease: implications for clinical diversity and treatment. Fertrin KY; Costa FF Expert Rev Hematol; 2010 Aug; 3(4):443-58. PubMed ID: 21083035 [TBL] [Abstract][Full Text] [Related]
49. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia. Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220 [TBL] [Abstract][Full Text] [Related]
50. Hydroxyurea and sickle cell disease: a chance for every patient. Weiner DL; Brugnara C JAMA; 2003 Apr; 289(13):1692-4. PubMed ID: 12672739 [No Abstract] [Full Text] [Related]
51. Hydroxyurea, sickle cell disease and renal transplantation. Allen A; Scoble J; Snowden S; Hambley H; Bellingham A Nephron; 1997; 75(1):106-7. PubMed ID: 9031282 [No Abstract] [Full Text] [Related]
52. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors. Okam MM; Ebert BL Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210 [TBL] [Abstract][Full Text] [Related]